Logo
x

Search

Subscribe Now

Artiva Biotherapeutics

Artiva Biotherapeutics Doses First Patient with AlloNK in the P-I Study for Treating Lupus Nephritis

Artiva Biotherapeutics Doses First Patient with AlloNK in the P-I Study for Treating Lupus Nephritis

  • April 18, 2024
Artiva Biotherapeutics Receives the US FDA’s Fast Track Designation for AlloNK (AB-101) to Treat Lupus Nephritis

Artiva Biotherapeutics Receives the US FDA’s Fast Track Designation for AlloNK (AB-101) to Treat Lupus Nephritis

  • February 23, 2024
Image

Incisive News in 3 Shots.

Contact Us

Our Information

Follow Us

Copyright © 2024 PharmaShots - All Rights Reserved.